Who Optimizes SG&A Costs Better? Viatris Inc. or CymaBay Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Viatris Inc. and CymaBay Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, CymaBay Therapeutics, Inc. maintained a leaner approach, with expenses reaching around $51.95 million in the same year. This stark difference highlights Viatris's expansive operations compared to CymaBay's focused strategy. Despite the disparity, both companies have shown a commitment to refining their cost structures, with Viatris reducing its expenses by about 10% from its 2021 peak. As the industry evolves, the ability to manage these costs effectively will remain a key differentiator.